发现与克罗恩病患者停用英夫利西单抗后短期及中远期复发风险相关的候选生物标志物:一项基于蛋白质组学的研究
该研究在稳定联合治疗下停用英夫利西单抗的克罗恩病患者基线血清中,通过鸟枪蛋白质组学发现和选择反应监测验证候选生物标志物,并按短期(<6个月)与中远期(>6个月)复发分层分析。结果显示,与短期复发风险相关的候选蛋白15种(2.9<HR<16.1,p<0.05),与中远期复发风险相关的候选蛋白17种(2.1<HR<4.7,p<0.05)。新型标志物组合的预测能力高于C反应蛋白和粪钙卫蛋白。
要点
- 停用英夫利西单抗的克罗恩病患者中,15种蛋白与短期复发风险相关(2.9<HR<16.1,p<0.05)。
- 17种蛋白与中远期复发风险相关(2.1<HR<4.7,p<0.05),反映不同病理生理过程。
- 新型标志物组合的预测能力高于C反应蛋白和粪钙卫蛋白(错误发现率<0.001)。
核心结论
- 首次发现与克罗恩病患者停用英夫利西单抗后中远期复发风险相关的循环候选生物标志物。
- 研究揭示了一系列导致复发的病理生理过程,可能有助于更好地理解疾病进展。
- 研究结果可能为考虑停用抗肿瘤坏死因子α时更好地无创评估复发风险铺平道路。
研究设计与样本
- 在联合治疗(抗代谢药和英夫利西单抗)且临床稳定缓解的克罗恩病患者停用英夫利西单抗时,于基线血清中寻找新的复发生物标志物(diSconTinuation in CrOhn's disease patients in stable Remission on combined therapy with Immunosuppressors队列,n=102)。
- 通过鸟枪蛋白质组学实验(发现步骤)鉴定候选生物标志物,并进一步用选择反应监测进行靶向验证(验证步骤)。
- 数据集按短期(<6个月)或中远期(>6个月)复发进行分层,以寻找相应标志物。
- 使用单变量Cox模型评估候选生物标志物相关的复发风险,使用对数秩统计量评估其预测能力。
- 为检验候选生物标志物的互补预测能力,将其系统性地两两组合。
主要发现
- 15种蛋白与短期复发风险相关(2.9<HR<16.1,p<0.05)。
- 17种蛋白与中远期复发风险相关(2.1<HR<4.7,p<0.05),这些蛋白反映不同的病理生理过程。
- 在分层和非分层数据集中,新型标志物组合表现出高预测能力,其Z评分高于C反应蛋白和粪钙卫蛋白(错误发现率<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: A subset of Crohn's disease (CD) patients experiences mid/long-term remission after infliximab withdrawal. Biomarkers are needed to identify those patients. DESIGN: New biomarkers of relapse were searched in the baseline serum of CD patients stopping infliximab when they were under combined therapy (antimetabolite and infliximab) and stable clinical remission (diSconTinuation in CrOhn's disease patients in stable Remission on combined therapy with Immunosuppressors cohort, n=102). From shotgun proteomics experiment (discovery step), biomarker candidates were identified and further targeted by selected reaction monitoring (verification step). The dataset was stratified to search for markers of short-term (<6 months) or mid/long-term relapse (>6 months). The risk of relapse and the predicting capacity associated with biomarker candidates were evaluated using univariate Cox model and log-rank statistic, respectively. To test their complementary predicting capacity, biomarker candidates were systematically combined in pairs. RESULTS: Distinct biomarker candidates were associated with the risk (HR) of short-term (15 proteins, 2.9<HR<16.1, p<0.05) and mid/long-term (17 proteins, 2.1<HR<4.7, p<0.05) relapse, they reflect different pathophysiological processes. In stratified and non-stratified datasets, novel marker combinations exhibited a high predicting capacity as shown by their higher Z-scores (false discovery rate <0.001) than C reactive protein and faecal calprotectin (current references in predicting relapse). CONCLUSION: We identified for the first time circulating biomarker candidates associated with the risk of mid/long-term relapse in CD patients stopping infliximab. We also highlight a sequence of pathophysiological processes leading to relapse, this could help to better understand the disease progression. Our findings may pave the way for a better non-invasive evaluation of the risk of relapse when contemplating antitumour necrosis factor α withdrawal in CD patients.
引用
- Pierre N, Baiwir D, Huynh-Thu VA, et al. Discovery of biomarker candidates associated with the risk of short-term and mid/long-term relapse after infliximab withdrawal in Crohn's patients: a proteomics-based study. Gut. 2020. PMID: 33106355. doi:10.1136/gutjnl-2020-322100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。